BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 18504438)

  • 41. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
    Liu HJ; Li GL; Lei PC
    Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
    [No Abstract]   [Full Text] [Related]  

  • 42. Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma.
    García-López J; Wallace K; Otero JH; Olsen R; Wang YD; Finkelstein D; Gudenas BL; Rehg JE; Northcott P; Davidoff AM; Freeman KW
    Cell Rep; 2020 Jan; 30(2):454-464.e5. PubMed ID: 31940489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.
    Swarbrick A; Woods SL; Shaw A; Balakrishnan A; Phua Y; Nguyen A; Chanthery Y; Lim L; Ashton LJ; Judson RL; Huskey N; Blelloch R; Haber M; Norris MD; Lengyel P; Hackett CS; Preiss T; Chetcuti A; Sullivan CS; Marcusson EG; Weiss W; L'Etoile N; Goga A
    Nat Med; 2010 Oct; 16(10):1134-40. PubMed ID: 20871609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The MYCN oncogene and differentiation in neuroblastoma.
    Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
    Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
    Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
    J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
    Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.
    Coco S; Defferrari R; Scaruffi P; Cavazzana A; Di Cristofano C; Longo L; Mazzocco K; Perri P; Gambini C; Moretti S; Bonassi S; Tonini GP
    J Pathol; 2005 Nov; 207(3):346-57. PubMed ID: 16178058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Silencing of Long Non-coding RNA LINC01106 Represses Malignant Behaviors of Gastric Cancer Cells by Targeting miR-34a-5p/MYCN Axis.
    Hong S; Li Q; Yang Y; Jing D; Zhu F
    Mol Biotechnol; 2022 Feb; 64(2):144-155. PubMed ID: 34550549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
    Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
    Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.
    Lynch J; Fay J; Meehan M; Bryan K; Watters KM; Murphy DM; Stallings RL
    Carcinogenesis; 2012 May; 33(5):976-85. PubMed ID: 22382496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
    Slack A; Lozano G; Shohet JM
    Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status.
    Guo X; Chen QR; Song YK; Wei JS; Khan J
    BMC Med Genomics; 2011 Apr; 4():35. PubMed ID: 21501490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
    Bray I; Bryan K; Prenter S; Buckley PG; Foley NH; Murphy DM; Alcock L; Mestdagh P; Vandesompele J; Speleman F; London WB; McGrady PW; Higgins DG; O'Meara A; O'Sullivan M; Stallings RL
    PLoS One; 2009 Nov; 4(11):e7850. PubMed ID: 19924232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of CHD5 Inactivation in neuroblastomas.
    Koyama H; Zhuang T; Light JE; Kolla V; Higashi M; McGrady PW; London WB; Brodeur GM
    Clin Cancer Res; 2012 Mar; 18(6):1588-97. PubMed ID: 22294723
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
    Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
    Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
    Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
    N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.